Based on these findings, we hypothesized that simultaneous inhibition of AXL and SRC could effectively suppress this feedback loop, reduce KRAS-driven signaling and enhance the therapeutic potential of Dasatinib in KRAS mutant NSCLC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.